Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TransMedics Group Total Payout Ratio Related Terms
TransMedics Group Total Payout Ratio Historical Data
* Premium members only.
The historical data trend for TransMedics Group's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMDX vs ESTA, AXGN, NVCR: Total Payout Ratio Comparison
For the Medical Devices subindustry, TransMedics Group's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group Total Payout Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where TransMedics Group's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group (TMDX) has a Total Payout Ratio of 0.00 as of Aug. 11, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on TransMedics Group and its competitors.
Is TransMedics Group's Total Payout Ratio too high?
TransMedics Group's current Total Payout Ratio is 0.00. Overall, TransMedics Group has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's Total Payout Ratio compare to ESTA and AXGN?
TransMedics Group's Total Payout Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Devices & Instruments company?
A good Total Payout Ratio depends on the Medical Devices & Instruments industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on TransMedics Group and its competitors. TransMedics Group's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $156.44, compared to a current price of $89.36 — trading 42.9% below its estimated fair value. The current Total Payout Ratio is 0.00. TransMedics Group's overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For TransMedics Group (TMDX), the current Total Payout Ratio is 0.00 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (TMDX) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of $89.36 is trading 42.9% below its estimated GF Value™ of $156.44.
GuruFocus considers TransMedics Group to be Possible Value Trap.
Key valuation signals for TMDX:
Total Payout Ratio: 0.00
GF Value™: $156.44 vs. price of $89.36 (42.9% below fair value)
No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
75GF Score
Get the complete analysis for TMDX
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMDX has been successfully added to your 
